Vassilakopoulou Vyronia, Karachaliou Chrysoula-Evangelia, Evangelou Alexandra, Zikos Christos, Livaniou Evangelia
Immunopeptide Chemistry Lab., Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety (INRASTES), National Centre for Scientific Research "Demokritos", Patr. Grigoriou E' & 27 Neapoleos St., 15341 Agia Paraskevi, Greece.
Department of Wine, Vine and Beverage Sciences, University of West Attica, 12243 Athens, Greece.
Vaccines (Basel). 2021 Nov 4;9(11):1278. doi: 10.3390/vaccines9111278.
The development of peptide-based vaccines for treating human neurodegenerative diseases has been the eventual aim of many research endeavors, although no active immunotherapies have been approved for clinical use till now. A typical example of such endeavors is the effort to develop vaccines for Alzheimer's disease based on the beta-amyloid peptide, which continues to be intensively investigated despite previous setbacks. In this paper, recent developments in peptide-based vaccines which target beta-amyloid as well as tau protein and α-synuclein are presented. Particular focus has been directed toward peptide epitopes and formulation systems selected/developed and employed to enhance vaccine efficacy and safety. Results from both, human clinical trials and animal preclinical studies conducted mainly in transgenic mice have been included. Future perspectives on the topic are also briefly discussed.
开发用于治疗人类神经退行性疾病的肽基疫苗一直是许多研究工作的最终目标，尽管迄今为止尚无主动免疫疗法获批用于临床。此类研究工作的一个典型例子是基于β-淀粉样肽开发阿尔茨海默病疫苗的努力，尽管此前遭遇挫折，但该研究仍在深入进行。本文介绍了针对β-淀粉样蛋白、tau蛋白和α-突触核蛋白的肽基疫苗的最新进展。特别关注了为提高疫苗效力和安全性而选择/开发并采用的肽表位和制剂系统。文中纳入了人体临床试验和主要在转基因小鼠中进行的动物临床前研究的结果。还简要讨论了该主题的未来前景。
